The Aarnate 60mg Injection contains the drug Artesunate, mainly intended for the eradication of malaria, specifically in critical conditions. The drug is part of the artemisinin category and is featured on the World Health Organization's List of Essential Medicines.

Functioning as a prodrug, it promptly converts into its active version, the dihydroartemisinin (DHA). The conversion triggers reactive oxygen species generation, leading to oxidative stress and damage to malaria-causing proteins. Besides, it blocks the essential Plasmodium falciparum exported protein 1 (EXP1), thereby lowering parasite glutathione levels.

While the tolerance level is generally high , common adverse effects might comprise slow pulse rate, allergic responses, vertigo, and diminished white blood cell levels. In extreme conditions, cases of kidney failure needing dialysis, hemoglobinuria (appearance of hemoglobin in urine), and jaundice have been documented.

It is believed to be safe during gestation, especially during the latter two trimesters, yet caution is recommended during the initial trimester. It is largely secure for pediatric use, with dosage adjustments necessary for those below 20 kg. In particular, it should be avoided in newborns when mixed with sulfadoxine/pyrimethamine because of potential impacts on bilirubin.

In case of a skipped dose, it is vital to seek advice from a healthcare expert to recommend the best course of action. The time and severity of the missed dosage will be taken into account for determining the proper response.